Table 1 Baseline clinical characteristics according to ESR
|  | Overall | Normal group (ESR ≤ 15 mm/h) | Elevated group (ESR > 15 mm/h) | P-value |
|---|---|---|---|---|
Number | 483 | 359 | 124 | Â |
Demographic data | ||||
 Age (years) ** | 63.1 ± 12.61 | 61.9 ± 12.50 | 67.0 ± 12.14 | < 0.001 |
 Male (%) ** | 374 (77.4%) | 301 (83.8%) | 73 (58.9%) | < 0.001 |
 BMI (kg/m2) | 25.2 (23.2, 27.7) | 25.4 (23.4, 28.7) | 24.9 (22.8, 26.7) | 0.04 |
 Heart rate (beats/min) | 78.1 ± 15.36 | 77.8 ± 14.65 | 78.8 ± 17.29 | 0.57 |
 Systolic pressure (mmHg) | 123.1 ± 22.35 | 123.3 ± 21.66 | 122.6 ± 24.35 | 0.77 |
 White blood cell (×109/L) | 10.4 ± 3.13 | 10.6 ± 3.09 | 9.9 ± 3.22 | 0.04 |
 Neutrophil (%) | 79.3 ± 10.77 | 79.8 ± 10.66 | 78.0 ± 11.03 | 0.12 |
 HGB (g/L) ** | 133.9 ± 17.79 | 137.7 ± 16.27 | 122.8 ± 17.42 | < 0.001 |
 Platelet (×109/L)** | 208 (172, 237) | 205 (170, 231) | 225.5 (178, 261) | < 0.001 |
 Cholesterol (mmol/L) | 4.5 ± 1.11 | 4.5 ± 1.11 | 4.6 ± 1.11 | 0.36 |
 HDL (mmol/L) | 1.1 ± 0.29 | 1.1 ± 0.30 | 1.0 ± 0.27 | 0.12 |
 LDL (mmol/L) | 2.8 ± 0.94 | 2.8 ± 0.93 | 2.9 ± 0.95 | 0.30 |
 Triglyceride (mmol/L) | 1.7 ± 1.47 | 1.7 ± 1.58 | 1.6 ± 1.11 | 0.41 |
 hs-CRP (mg/L) * | 5.4 (2.29, 11.13) | 4.4 (2.06, 10.16) | 11.0 (4.37, 13.06) | < 0.01 |
 Creatinine (μmol/L) | 76.4 (65.4, 93.6) | 76.4 (65.6, 88.4) | 76.3 (64.8, 106.1) | 0.18 |
 Fasting glucose (mmol/L) | 8.3 ± 3.97 | 8.0 ± 3.80 | 8.9 ± 4.38 | 0.05 |
 BNP (pg/ml) * | 127.0 (45.4, 382.0) | 93.7(39.6, 271.0) | 255 (123.0, 656) | < 0.01 |
 CTNI (ng/mL) | 30.1 (9.21, 77.39) | 32.0 (10.74,79.8) | 25.2 (5.44, 69.46) | 0.08 |
 EF (%) | 60 (50,67) | 60 (51, 68) | 59 (48.5,65) | 0.05 |
Risk factors | ||||
 Hypertension (%) * | 290 (60.0%) | 259 (55.7%) | 90 (72.6%) | < 0.01 |
 Diabetes mellitus (%) | 175(36.2%) | 119 (33.1%) | 56 (45.2%) | 0.02 |
 Hyperlipidemia (%) | 138 (28.8%) | 358 (29.3%) | 33 (27.1%) | 0.63 |
 Smoking (%) * * | 295 (61.1%) | 238 (66.3%) | 57 (46.0%) | < 0.001 |
 Previous PCI (%) | 45 (9.3%) | 36 (10.0%) | 9 (7.2%) | 0.47 |
 Previous MI (%) | 59 (12.2%) | 45 (12.6%) | 14 (11.3%) | 0.78 |
 COPD (%) * | 16 (3.3%) | 7 (2.0%) | 9 (7.3%) | < 0.01 |
 PVD (%) | 54 (11.2%) | 34 (9.5%) | 20 (16.1%) | 0.04 |
 Asthma (%) | 2 (0.4%) | 2(0.6%) | 0(0.0%) | 0.41 |
 Rheumatoid arthritis (%) | 3 (0.62%) | 1(0.3%) | 2 (1.6%) | 0.10 |
 Gout (%) | 8 (1.7%) | 7 (2.0%) | 1 (0.8%) | 0.39 |
 Psoriasis (%) | 2 (0.4%) | 1 (0.3%) | 1 (0.8%) | 0.43 |
 OSAHS (%) | 6 (1.0%) | 5 (1.4%) | 0 (0.0%) | 0.19 |
 Chronic kidney disease (%) * * | 17(3.5%) | 6 (1.7%) | 11 (8.9%) | < 0.001 |
Infarct-related artery | ||||
 Left main artery (%) * | 5(1.0%) | 5 (1.4%) | 0 (0%) | < 0.01 |
 Left anterior descending artery (%) | 193 (40.0%) | 136(37.9%) | 57 (46.0%) | 0.16 |
 Left circumflex artery (%) | 74(15.3%) | 58 (16.2%) | 16 (12.9%) | 0.39 |
 Right coronary artery (%) | 211(43.7%) | 160 (44.6%) | 51 (41.1%) | 0.51 |
 SYNTAX score | 26.5 ± 9.61 | 26.6 ± 9.96 | 26.3 ± 8.56 | 0.74 |
 SSII* * | 32.3 ± 11.34 | 30.6 ± 10.98 | 37.1 ± 11.04 | < 0.001 |
MACE | ||||
 Follow-up time (months) * | 25 (20, 35) | 27 (21, 36) | 22 (10.5, 30) | < 0.01 |
 Mortality (%) | 28 (5.8%) | 16 (4.5%) | 12 (9.7%) | 0.03 |
 Heart failure (%) ** | 43 (8.9%) | 16 (4.5%) | 27 (21.8%) | < 0.001 |
 Recurrent MI (%) | 21 (4.4%) | 18 (5.0%) | 3 (2.4%) | 0.22 |
 Revascularization (%) | 65 (13.5%) | 41(11.4%) | 24 (19.4%) | 0.03 |
 Nonfatal stroke (%) | 6 (1.2%) | 2(0.6%) | 4 (1.6%) | 0.04 |
 MACE (%) ** | 139 (27.8%) | 82 (22.8%) | 57 (46.0%) | < 0.001 |